Abstract
Mesothelioma is an uncommon tumor. It has a latency period of 20-40 years. The most important risk factor is asbestos exposure. Prognosis of mesothelioma is generally poor with high case-fatality rate, and research to improve the outcome of this disease is on-going worldwide. Due to its rarity, management by a multidisciplinary team with experience is recommended. Carefully selected patients may benefit from tri-modality (surgery, radiotherapy and chemotherapy) treatment. The management of pleural and peritoneal mesothelioma is summarized in this review. Recent advances in chemotherapy and biologic response modifiers are promising.
Keywords: Asbestos, epidemiology, treatment, Mesothelioma, tri-modality (surgery, radiotherapy and chemotherapy), pleural and peritoneal mesothelioma, malignant meosothelioma
Current Respiratory Medicine Reviews
Title: Mesothelioma - Epidemiology and Management
Volume: 7 Issue: 5
Author(s): Patricia Tai, Edward Yu, Avi Assouline and Kurian Joseph
Affiliation:
Keywords: Asbestos, epidemiology, treatment, Mesothelioma, tri-modality (surgery, radiotherapy and chemotherapy), pleural and peritoneal mesothelioma, malignant meosothelioma
Abstract: Mesothelioma is an uncommon tumor. It has a latency period of 20-40 years. The most important risk factor is asbestos exposure. Prognosis of mesothelioma is generally poor with high case-fatality rate, and research to improve the outcome of this disease is on-going worldwide. Due to its rarity, management by a multidisciplinary team with experience is recommended. Carefully selected patients may benefit from tri-modality (surgery, radiotherapy and chemotherapy) treatment. The management of pleural and peritoneal mesothelioma is summarized in this review. Recent advances in chemotherapy and biologic response modifiers are promising.
Export Options
About this article
Cite this article as:
Tai Patricia, Yu Edward, Assouline Avi and Joseph Kurian, Mesothelioma - Epidemiology and Management, Current Respiratory Medicine Reviews 2011; 7(5) . https://dx.doi.org/10.2174/157339811797189731
DOI https://dx.doi.org/10.2174/157339811797189731 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Antibody-Drug Conjugate Targets
Current Cancer Drug Targets Focal Adhesion Kinase: From In Vitro Studies to Functional Analyses In Vivo
Current Protein & Peptide Science Malignant Pleural Mesothelioma in 2011. Is there a Gold Standard Therapy?
Current Respiratory Medicine Reviews Bisphosphonates: Molecular Mechanisms of Action and Effects on Bone Cells, Monocytes and Macrophages
Current Pharmaceutical Design Cancer-Targeted Oncolytic Adenoviruses for Modulation of the Immune System
Current Cancer Drug Targets Melanoma
Current Cancer Therapy Reviews subject Index To Volume 1
Current Molecular Medicine Ligand-Targeted Liposomal Therapies of Neuroblastoma
Current Medicinal Chemistry Antibody-Targeted RNase Fusion Proteins (ImmunoRNases) for Cancer Therapy
Current Pharmaceutical Biotechnology Progress of HDAC Inhibitor Panobinostat in the Treatment of Cancer
Current Drug Targets Telomere Recombination and the ALT Pathway: A Therapeutic Perspective for Cancer
Current Pharmaceutical Design Targeting CREB for Cancer Therapy: Friend or Foe
Current Cancer Drug Targets Functional Role of Glycosphingolipids in Cancer
Current Medicinal Chemistry Is α7-nAChR a Possible Target for Lung Cancer and Malignant Pleural Mesothelioma Treatment?
Current Drug Targets DNA Methylation Markers in Lung Cancer
Current Genomics Using Pharmacologic Data to Plan Clinical Treatments for Patients with Peritoneal Surface Malignancy
Current Drug Discovery Technologies DLEU2: A Meaningful Long Noncoding RNA in Oncogenesis
Current Pharmaceutical Design New Developments in the Management of Pleural Effusions
Current Respiratory Medicine Reviews Overview on Anticancer Drug Design and Development
Current Medicinal Chemistry Onconeural Versus Paraneoplastic Antigens?
Current Medicinal Chemistry